Tiziana Life Sciences Ltd - Company Profile
Powered by 
All the sales intelligence you need on Tiziana Life Sciences Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Tiziana Life Sciences Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Tiziana Life Sciences Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Tiziana Life Sciences Ltd (Tiziana) is a clinical-stage biotechnology company. It is developing therapies for neurodegenerative and lung diseases, with a clinical pipeline targeting secondary progressive multiple sclerosis (SPMS), amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, and KRAS-positive non-small cell lung cancer (NSCLC). The company’s product pipeline includes foralumab, a fully human anti-CD3 monoclonal antibody in clinical development for neurodegenerative diseases and Crohn’s disease. Foralumab offers a shorter treatment duration and reduced immunogenicity, and a patent application has been submitted for its use in enhancing CAR-T therapies. The company is also evaluating Milciclib, which targets cancer progression pathways, and the anti-IL-6R monoclonal antibody TZLS-501, which addresses chronic inflammation. Tiziana is headquartered in Hamilton, Bermuda.
Headquarters
Bermuda
Address
Clarendon House, 2 Church Street, Hamilton, HM11
Website
www.tizianalifesciences.com
Telephone
44 207 4952379
No of Employees
10
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
TLSA (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-55.4%
(2024 vs 2023)
Market Cap*
$132.4M
* As of and is in US$
Tiziana Life Sciences Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline: |
| Foralumab: Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, Amyotrophic Lateral Sclerosis and Intracerebral Hemorrhage (ICH) |
| TZLS-501: Inflammatory Diseases |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Acquisitions/Mergers/Takeovers | In July, the company announced that its Executive Chairman Gabriele Cerrone purchased certain common shares. |
| 2021 | Contracts/Agreements | In September, the company announced exclusive license agreement with Precision BioSciences to evaluate Foralumab in conjunction with allogeneic CAR T candidates for cancer treatment. |
| 2021 | Contracts/Agreements | In June, the company and FHI Clinical entered into an agreement to Conduct a Phase 2 Clinical Trial for Treating Hospitalized Severe COVID-19 Patients with Intranasal Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody. |
Competitor Comparison
| Key Parameters | Tiziana Life Sciences Ltd | MeiraGTx Holdings Plc | Prime Medicine Inc | Crescendo Biologics Ltd | Annexon Inc |
|---|---|---|---|---|---|
| Headquarters | Bermuda | United States of America | United States of America | United Kingdom | United States of America |
| City | Hamilton | New York City | Cambridge | Cambridge | Brisbane |
| State/Province | - | New York | Massachusetts | England | California |
| No. of Employees | 10 | 403 | 146 | 52 | 96 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Gabriele Marco Antonio Cerrone | Chairman | Executive Board | 2014 | 53 |
| Ivor Elrifi | Director; Chief Executive Officer | Executive Board | 2024 | 64 |
| Keeren Shah | Chief Operating Officer; Chief Financial Officer | Senior Management | - | - |
| Richard Kim | Chief Medical Officer | Senior Management | - | - |
| William A. Clementi, Ph.D. | Chief Development Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer